Patent ID: 9540431
Date: 2017-01-10
CPC Classifications: A61K,A61P,C07K,G01N

Claim:
1. A method for treating myelodysplastic syndrome (MDS) in a patient, comprising the step of administering a fusion protein APG101 comprising an extracellular CD95R domain having the amino acid sequence 26-172 of SEQ ID NO: 1 and a human Fc domain having the amino acid sequence 172-400 of SEQ ID NO: 1 to a patient in need thereof, wherein the MDS is selected from the IPSS low-risk MDS subgroup and/or the IPSS intermediate-1 (int-1) risk MDS subgroup, and the fusion protein binds to CD95 ligand (CD95L) and inhibits CD95 signalling pathway.